| Rank | % of international placing | % of global offering |
|---|---|---|
| Top 5 | 80.71% | 72.64% |
| Top 10 | 89.97% | 80.97% |
| Top 25 | 97.55% | 87.79% |
The IPO attracted staggering demand with an oversubscription ratio of 6697.8x, reflecting extreme market enthusiasm for the biomedical sector. The hit rate of just 3.12% indicates severe allocation scarcity, typical of hot Hong Kong IPOs where retail investors scramble for minimal shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
A notable inefficiency exists between the A-tail and B-head: applying HKD 300,000 yields just 0.0533 expected lots, while HKD 400,000 yields 0.083 lots, offering a minuscule marginal gain of only 0.0297 lots for an extra HKD 100,000. This suggests that the marginal benefit of moving from the top of A-tier to the bottom of B-tier is extremely poor, making lower-tier applications almost as effective. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographic data is not available for this IPO, preventing any analysis of mainland China participation, gender, or regional distribution. Without such information, we cannot identify typical patterns like Guangdong dominance or broad cross-border interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for CF Pharmtech (02652): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

